Does the media prefer ONC or BMY?

In the previous week, Bristol Myers Squibb had 13 more articles in the media than BeOne Medicines. MarketBeat recorded 30 mentions for Bristol Myers Squibb and 17 mentions for BeOne Medicines. Bristol Myers Squibb's average media sentiment score of 0.73 beat BeOne Medicines' score of 0.46 indicating that Bristol Myers Squibb is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 6 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bristol Myers Squibb 11 Very Positive mention(s) 8 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 3 Very Negative mention(s) Positive

Which has stronger earnings & valuation, ONC or SNY?

Sanofi has higher revenue and earnings than BeOne Medicines. Sanofi is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BeOne Medicines $5.34B 7.36 $286.93M $5.68 63.04 Sanofi $49.35B 1.96 $8.84B $1.91 20.90

Is ONC or SNY more profitable?

BeOne Medicines has a net margin of 10.70% compared to Sanofi's net margin of 8.66%. BeOne Medicines' return on equity of 14.23% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets BeOne Medicines 10.70% 14.23% 7.82% Sanofi 8.66% 14.19% 7.95%

Does the media prefer ONC or SNY?

In the previous week, BeOne Medicines had 5 more articles in the media than Sanofi. MarketBeat recorded 17 mentions for BeOne Medicines and 12 mentions for Sanofi. Sanofi's average media sentiment score of 0.46 beat BeOne Medicines' score of 0.46 indicating that Sanofi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 6 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sanofi 2 Very Positive mention(s) 5 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, ONC or GSK?

GSK has higher revenue and earnings than BeOne Medicines. GSK is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BeOne Medicines $5.34B 7.36 $286.93M $5.68 63.04 GSK $43.07B 2.21 $7.54B $3.20 14.70

Is ONC or GSK more profitable?

GSK has a net margin of 14.56% compared to BeOne Medicines' net margin of 10.70%. GSK's return on equity of 43.23% beat BeOne Medicines' return on equity. Company Net Margins Return on Equity Return on Assets BeOne Medicines 10.70% 14.23% 7.82% GSK 14.56% 43.23% 11.60%

Does the media prefer ONC or GSK?

In the previous week, BeOne Medicines had 12 more articles in the media than GSK. MarketBeat recorded 17 mentions for BeOne Medicines and 5 mentions for GSK. BeOne Medicines' average media sentiment score of 0.46 beat GSK's score of -0.12 indicating that BeOne Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 6 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GSK 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ONC or TAK?

BeOne Medicines presently has a consensus target price of $404.14, suggesting a potential upside of 12.87%. Given BeOne Medicines' stronger consensus rating and higher possible upside, equities research analysts plainly believe BeOne Medicines is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeOne Medicines 0 Sell rating(s) 2 Hold rating(s) 12 Buy rating(s) 3 Strong Buy rating(s) 3.06 Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media prefer ONC or TAK?

In the previous week, BeOne Medicines had 3 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 17 mentions for BeOne Medicines and 14 mentions for Takeda Pharmaceutical. BeOne Medicines' average media sentiment score of 0.46 beat Takeda Pharmaceutical's score of 0.29 indicating that BeOne Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 6 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Takeda Pharmaceutical 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

BeOne Medicines (ONC) Competitors

$358.07 -0.70 (-0.20%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$358.30 +0.23 (+0.06%)

As of 10/2/2026 07:30 PM Eastern

Compare

ONC vs. BMY, SNY, GSK, TAK, and TEVA

Should you buy BeOne Medicines stock or one of its competitors? BeOne Medicines's main competitors and comparable companies include Bristol Myers Squibb (BMY), Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), and Teva Pharmaceutical Industries (TEVA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does BeOne Medicines compare to Bristol Myers Squibb?

BeOne Medicines (NASDAQ:ONC) and Bristol Myers Squibb (NYSE:BMY) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

Bristol Myers Squibb has higher revenue and earnings than BeOne Medicines. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	7.36	$286.93M	$5.68	63.04
Bristol Myers Squibb	$48.19B	2.59	$7.05B	$4.54	13.47

Bristol Myers Squibb has a net margin of 18.87% compared to BeOne Medicines' net margin of 10.70%. Bristol Myers Squibb's return on equity of 66.90% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	10.70%	14.23%	7.82%
Bristol Myers Squibb	18.87%	66.90%	14.74%

BeOne Medicines presently has a consensus target price of $404.14, indicating a potential upside of 12.87%. Bristol Myers Squibb has a consensus target price of $67.06, indicating a potential upside of 9.65%. Given BeOne Medicines' stronger consensus rating and higher possible upside, research analysts plainly believe BeOne Medicines is more favorable than Bristol Myers Squibb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	0 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.06
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.60

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 76.4% of Bristol Myers Squibb shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by company insiders. Comparatively, 0.1% of Bristol Myers Squibb shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

BeOne Medicines has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Bristol Myers Squibb has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market.

In the previous week, Bristol Myers Squibb had 13 more articles in the media than BeOne Medicines. MarketBeat recorded 30 mentions for Bristol Myers Squibb and 17 mentions for BeOne Medicines. Bristol Myers Squibb's average media sentiment score of 0.73 beat BeOne Medicines' score of 0.46 indicating that Bristol Myers Squibb is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	6 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bristol Myers Squibb	11 Very Positive mention(s)	8 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Positive

Summary

BeOne Medicines and Bristol Myers Squibb tied by winning 8 of the 16 factors compared between the two stocks.

How does BeOne Medicines compare to Sanofi?

BeOne Medicines (NASDAQ:ONC) and Sanofi (NASDAQ:SNY) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

Sanofi has higher revenue and earnings than BeOne Medicines. Sanofi is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	7.36	$286.93M	$5.68	63.04
Sanofi	$49.35B	1.96	$8.84B	$1.91	20.90

In the previous week, BeOne Medicines had 5 more articles in the media than Sanofi. MarketBeat recorded 17 mentions for BeOne Medicines and 12 mentions for Sanofi. Sanofi's average media sentiment score of 0.46 beat BeOne Medicines' score of 0.46 indicating that Sanofi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	6 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sanofi	2 Very Positive mention(s)	5 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

BeOne Medicines has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market.

BeOne Medicines currently has a consensus target price of $404.14, suggesting a potential upside of 12.87%. Sanofi has a consensus target price of $49.50, suggesting a potential upside of 24.00%. Given Sanofi's higher probable upside, analysts plainly believe Sanofi is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	0 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.06
Sanofi	1 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.38

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by company insiders. Comparatively, 1.0% of Sanofi shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

BeOne Medicines has a net margin of 10.70% compared to Sanofi's net margin of 8.66%. BeOne Medicines' return on equity of 14.23% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	10.70%	14.23%	7.82%
Sanofi	8.66%	14.19%	7.95%

Summary

BeOne Medicines beats Sanofi on 12 of the 17 factors compared between the two stocks.

How does BeOne Medicines compare to GSK?

BeOne Medicines (NASDAQ:ONC) and GSK (NYSE:GSK) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

BeOne Medicines has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market. Comparatively, GSK has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market.

In the previous week, BeOne Medicines had 12 more articles in the media than GSK. MarketBeat recorded 17 mentions for BeOne Medicines and 5 mentions for GSK. BeOne Medicines' average media sentiment score of 0.46 beat GSK's score of -0.12 indicating that BeOne Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	6 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GSK	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

BeOne Medicines currently has a consensus price target of $404.14, suggesting a potential upside of 12.87%. GSK has a consensus price target of $56.50, suggesting a potential upside of 20.07%. Given GSK's higher possible upside, analysts plainly believe GSK is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	0 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.06
GSK	2 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.09

GSK has higher revenue and earnings than BeOne Medicines. GSK is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	7.36	$286.93M	$5.68	63.04
GSK	$43.07B	2.21	$7.54B	$3.20	14.70

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by insiders. Comparatively, 10.0% of GSK shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

GSK has a net margin of 14.56% compared to BeOne Medicines' net margin of 10.70%. GSK's return on equity of 43.23% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	10.70%	14.23%	7.82%
GSK	14.56%	43.23%	11.60%

Summary

BeOne Medicines beats GSK on 10 of the 17 factors compared between the two stocks.

How does BeOne Medicines compare to Takeda Pharmaceutical?

BeOne Medicines (NASDAQ:ONC) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

BeOne Medicines has a net margin of 10.70% compared to Takeda Pharmaceutical's net margin of 3.80%. BeOne Medicines' return on equity of 14.23% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	10.70%	14.23%	7.82%
Takeda Pharmaceutical	3.80%	10.95%	5.34%

In the previous week, BeOne Medicines had 3 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 17 mentions for BeOne Medicines and 14 mentions for Takeda Pharmaceutical. BeOne Medicines' average media sentiment score of 0.46 beat Takeda Pharmaceutical's score of 0.29 indicating that BeOne Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	6 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Takeda Pharmaceutical	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

BeOne Medicines has higher earnings, but lower revenue than Takeda Pharmaceutical. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	7.36	$286.93M	$5.68	63.04
Takeda Pharmaceutical	$28.32B	2.02	-$1.01B	$0.34	52.55

BeOne Medicines has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, suggesting that its share price is 107% less volatile than the broader market.

BeOne Medicines presently has a consensus target price of $404.14, suggesting a potential upside of 12.87%. Given BeOne Medicines' stronger consensus rating and higher possible upside, equities research analysts plainly believe BeOne Medicines is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	0 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.06
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

BeOne Medicines beats Takeda Pharmaceutical on 16 of the 17 factors compared between the two stocks.

How does BeOne Medicines compare to Teva Pharmaceutical Industries?

BeOne Medicines (NASDAQ:ONC) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

BeOne Medicines currently has a consensus price target of $404.14, suggesting a potential upside of 12.87%. Teva Pharmaceutical Industries has a consensus price target of $44.67, suggesting a potential upside of 13.13%. Given Teva Pharmaceutical Industries' higher probable upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	0 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.06
Teva Pharmaceutical Industries	0 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.92

BeOne Medicines has a net margin of 10.70% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Teva Pharmaceutical Industries' return on equity of 32.64% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	10.70%	14.23%	7.82%
Teva Pharmaceutical Industries	4.08%	32.64%	6.34%

In the previous week, Teva Pharmaceutical Industries had 9 more articles in the media than BeOne Medicines. MarketBeat recorded 26 mentions for Teva Pharmaceutical Industries and 17 mentions for BeOne Medicines. Teva Pharmaceutical Industries' average media sentiment score of 0.55 beat BeOne Medicines' score of 0.46 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	6 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Teva Pharmaceutical Industries	7 Very Positive mention(s)	5 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Teva Pharmaceutical Industries has higher revenue and earnings than BeOne Medicines. BeOne Medicines is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	7.36	$286.93M	$5.68	63.04
Teva Pharmaceutical Industries	$17.26B	2.67	$1.41B	$0.60	65.80

BeOne Medicines has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market.

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Teva Pharmaceutical Industries beats BeOne Medicines on 9 of the 16 factors compared between the two stocks.

Get BeOne Medicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ONC vs. The Competition

Export

Metric	BeOne Medicines	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$39.31B	$12.27B	$7.15B	$13.28B
Dividend Yield	N/A	2.65%	2.54%	17.33%
P/E Ratio	63.04	802.26	274.71	26.04
Price / Sales	7.36	940.01	656.46	105.16
Price / Cash	91.61	86.66	78.87	52.62
Price / Book	9.00	10.52	10.93	6.31
Net Income	$286.93M	$2.86B	$3.51B	$362.16M
7 Day Performance	-0.77%	-1.58%	-2.00%	-1.66%
1 Month Performance	-0.05%	-5.55%	-6.19%	-4.68%
1 Year Performance	4.13%	-2.19%	8.03%	1.57%

BeOne Medicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ONC BeOne Medicines	3.6016 of 5 stars	$358.07 -0.2%	$404.14 +12.9%	+4.1%	$39.31B	$5.34B	63.04	12,000	Trending News Analyst Forecast Insider Trade Gap Down
BMY Bristol Myers Squibb	4.74 of 5 stars	$60.91 -0.9%	$67.06 +10.1%	+34.7%	$124.39B	$48.19B	13.41	32,500	Analyst Revision
SNY Sanofi	3.8504 of 5 stars	$39.84 -2.1%	$49.50 +24.3%	-21.6%	$96.58B	$49.35B	20.86	74,846	Trending News Analyst Downgrade Gap Down
GSK GSK	3.8564 of 5 stars	$47.01 -0.4%	$56.50 +20.2%	+8.7%	$95.10B	$43.07B	14.70	66,841	Dividend Cut
TAK Takeda Pharmaceutical	1.4814 of 5 stars	$17.83 -0.2%	N/A	+22.3%	$57.12B	$28.32B	52.43	47,000	News Coverage Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ONC) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BeOne Medicines (ONC) Competitors

ONC vs. BMY, SNY, GSK, TAK, and TEVA

How does BeOne Medicines compare to Bristol Myers Squibb?

Summary

How does BeOne Medicines compare to Sanofi?

Summary

How does BeOne Medicines compare to GSK?

Summary

How does BeOne Medicines compare to Takeda Pharmaceutical?

Summary

How does BeOne Medicines compare to Teva Pharmaceutical Industries?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONC vs. The Competition

BeOne Medicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BeOne Medicines (ONC) Competitors

ONC vs. BMY, SNY, GSK, TAK, and TEVA

How does BeOne Medicines compare to Bristol Myers Squibb?

Which has stronger earnings and valuation, ONC or BMY?

Is ONC or BMY more profitable?

Do analysts rate ONC or BMY?

Do institutionals & insiders believe in ONC or BMY?

Which has more volatility & risk, ONC or BMY?

Does the media prefer ONC or BMY?

Summary

How does BeOne Medicines compare to Sanofi?

Which has stronger earnings & valuation, ONC or SNY?

Does the media prefer ONC or SNY?

Which has more volatility & risk, ONC or SNY?

Do analysts recommend ONC or SNY?

Do insiders & institutionals hold more shares of ONC or SNY?

Is ONC or SNY more profitable?

Summary

How does BeOne Medicines compare to GSK?

Which has more volatility & risk, ONC or GSK?

Does the media prefer ONC or GSK?

Do analysts rate ONC or GSK?

Which has stronger valuation and earnings, ONC or GSK?

Do insiders and institutionals hold more shares of ONC or GSK?

Is ONC or GSK more profitable?

Summary

How does BeOne Medicines compare to Takeda Pharmaceutical?

Is ONC or TAK more profitable?

Does the media prefer ONC or TAK?

Do insiders and institutionals believe in ONC or TAK?

Which has higher earnings and valuation, ONC or TAK?

Which has more volatility and risk, ONC or TAK?

Do analysts recommend ONC or TAK?

Summary

How does BeOne Medicines compare to Teva Pharmaceutical Industries?

Do analysts recommend ONC or TEVA?

Is ONC or TEVA more profitable?

Does the media refer more to ONC or TEVA?

Which has higher valuation & earnings, ONC or TEVA?

Which has more volatility & risk, ONC or TEVA?

Do insiders & institutionals hold more shares of ONC or TEVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONC vs. The Competition

BeOne Medicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools